Pfizer is committed to leveraging our global presence and expertise to bring biosimilars to patients.
Pfizer has one of the largest portfolios of biosimilars on the market, including cancer therapies, supportive care, and inflammation products to provide patients with more treatment options
LEARN MORE3 ONCOLOGY mAb PRODUCTS
3 SUPPORTIVE CARE PRODUCTS
Additional treatment choices at a potentially lower cost to the healthcare system
Potential cost savings for the healthcare system
Focused on quality: Pfizer biosimilars are produced to meet the same high-quality standards as its biologics—using robust protocols for monitoring quality throughout every stage of the manufacturing process.
Pfizer has the manufacturing, supply experience, and resources to develop biosimilar medicines, delivering 15 million doses of biosimilars globally each year (as of 2022).
As of May 2022.
Pfizer is dedicating significant resources to building a sustainable future, including monetary investments in US-based capital projects over the next several years.
Resources for providers and health systems to integrate biosimilars through effective operational enablement, IT, monitoring, education, and communication
Pfizer provides the resources and support that patients and their loved ones need during treatment. Because at Pfizer, patients are at the core of what we do.
MAKING YOUR PATIENTS' SUPPORT NEEDS A PRIORITY. TOGETHER.
At Pfizer Oncology Together, patient support is important to us. We’re here to help patients:
At Pfizer Oncology Together™, patient support is at the core of everything we do. From helping to identify financial assistance options to connecting patients to resources for emotional support, your patients’ needs are our priority.
PfizerOncologyTogether.comAvailable on ThisIsLivingWithCancer.com, This Is for You is here to equip patients and those who care for them with ways to help better cope with challenges, expected and unexpected, so they can focus on the everyday moments that matter to them.
ThisIsLivingWithCancer.com
